Other insomnia
Methodology & AI Transparency ⓘ
Other insomnia Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Other insomnia—coded clinically as G47.09 across Sleep Disorders guidelines—combines iron/thyroid screening [Other insomnia G47.09] with structured follow-up of Nocturnal Oxygen Saturation in Other insomnia (G47.09: (SpO2)) (>= 94% nadir > 90% (G47.09)).
- 2 Real-world patient consensus: Diagnostic registry G47.09: Other insomnia is managed within Sleep Disorders.
- 3 Typical cash cost range: Clinicians assessing Other insomnia focus on sympathetic micro-arousals [Other insomnia G47.09] and targeted history.
- 4 Top reported side effects / signs: Key Sleep Disorders biomarkers for Other insomnia (G47.09): Insomnia Severity Index in Other insomnia (G47.09: (ISI)) & Nocturnal Oxygen Saturation in Other insomnia (G47.09: (SpO2)) (>= 94% nadir > 90% (G47.09)).
Ask our AI Specialists anything about Other insomnia
What Is Other insomnia?
Other insomnia—coded clinically as G47.09 across Sleep Disorders guidelines—combines iron/thyroid screening [Other insomnia G47.09] with structured follow-up of Nocturnal Oxygen Saturation in Other insomnia (G47.09: (SpO2)) (>= 94% nadir > 90% (G47.09)).
Pathophysiology, Underlying Causes & Clinical Presentation
Other insomnia (G47.09) alters sleep disorders homeostasis through sympathetic micro-arousals [Other insomnia G47.09]; clinical remission targets Nocturnal Oxygen Saturation in Other insomnia (G47.09: (SpO2)) within >= 94% nadir > 90% (G47.09).
Common Symptoms & Clinical Signs
- • Presentation of Other insomnia (G47.09): unrefreshing morning waking in Other insomnia (G47.09: despite adequate hours)
- • Secondary Other insomnia clinical sign: loud habitual snoring, in Other insomnia (G47.09: witnessed breathing pauses,)
- • Symptom flares in Other insomnia correlating with Insomnia Severity Index in Other insomnia (G47.09: (ISI)) deviation outside < 7 (G47.09)
- • Functional sleep disorders impact requiring iron/thyroid screening [Other insomnia G47.09] evaluation (G47.09)
Other insomnia Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G47.09 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Insomnia, Sleep Apnea & Sleep Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: Insomnia Severity Index in Other insomnia (G47.09: (ISI)) | < 7 (G47.09) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Nocturnal Oxygen Saturation in Other insomnia (G47.09: (SpO2)) | >= 94% nadir > 90% (G47.09) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Ferritin (Restless in Other insomnia (G47.09: Legs)) | > 75 ng/mL (G47.09) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Other insomnia
Treatment selection for Other insomnia depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Other insomnia)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Valsartan vs. other angiotensin II receptor blockers in the treatment of high: What a 13,110-Participant Study Found Valsartan administered at 160 or 320 mg is more effective at lowering BP than losartan 100 mg and shows comparable efficacy to other ARBs in patients with essential high blood pressure. International journal of clinical practice • 2009-05-15 • Meta-Analysis | N = 13,110 | 99/100 | PMID 19392925 ↗ |
| New Insights on Efficacy comparison of monotherapies and combination therapies for androgenetic: What a 3,133-Participant Study Found In recent years, combination therapies are showing significant promise as potential therapies. Dermatologic therapy • 2022-03-15 • Meta-Analysis | N = 3,133 | 99/100 | PMID 34897933 ↗ |
| New Insights on Combination Therapy in Androgenetic hair loss: A Network Meta-Analysis of: What a 3,012-Participant Study Found Based on the current studies, we found that the combination of Minoxidil with spironolactone, PRPF, flutamide, and finasteride may offer better treatment outcomes for patients with androgenetic hair loss. Aesthetic plastic surgery • 2026-07-15 • Meta-Analysis | N = 3,012 | 99/100 | PMID 42168420 ↗ |
| New Insights on Safety profile of telmisartan as single-drug treatment or combined with: What a 8,023-Participant Study Found The consolidated data show that telmisartan +/- HCTZ are well tolerated in patients of all ages and have placebo-like tolerabilities. Blood pressure. Supplement • 2008-06-15 • Randomized Controlled Trial | N = 8,023 | 96/100 | PMID 18705533 ↗ |
| New Insights on Telmisartan and amlodipine single-pill combinations vs amlodipine single-drug: What a 1,097-Participant Study Found Superior BP reductions were also seen with T40-T80/A5 vs A10, with BP goal rates at least as high as with A10; however, there was significantly more peripheral edema with A10 (27.2% vs 4.3% for pooled. Journal of clinical hypertension (Greenwich, Conn.) • 2011-07-15 • Randomized Controlled Trial | N = 1,097 | 96/100 | PMID 21762357 ↗ |
Other insomnia Patient Community & “People Like Me” Threads
Filter Other insomnia community threads and patient logs by age, biological sex, dosage, and treatment duration.